Estimates venous thromboembolism risk in ambulatory patients starting systemic cancer therapy.
Khorana VTE Risk Score: Clinical Guide
Browse Knowledge HubEstimates venous thromboembolism risk in ambulatory patients starting systemic cancer therapy.
Overview
Estimates venous thromboembolism risk in ambulatory patients starting systemic cancer therapy.
Clinical Significance
Higher scores indicate greater chemotherapy-associated VTE risk.
When to Use
- Use as structured clinical decision support when the required data are available and reliable.
How It Is Calculated
- The displayed variables are combined using the published equation, decision rule or weighted point system.
Interpretation
- Higher scores indicate greater chemotherapy-associated VTE risk.
Worked Example
Enter verified patient data in the displayed units; MedicalC applies the published model.
Limitations
- Risk and classification tools can be misapplied outside their validated population.
- Missing, estimated or non-contemporaneous data may materially change the result.
Clinical Pearls
- Document the inputs, units, date and clinical setting with the result.
- Use serial scores only when the same instrument and measurement method are used consistently.
Common Mistakes
- Using the tool without confirming entry criteria.
- Using approximate or incorrectly converted values.
- Treating a prognostic score as a standalone treatment decision.
Frequently Asked Questions
What does this tool calculate?
Estimates venous thromboembolism risk in ambulatory patients starting systemic cancer therapy.
Can this result be used alone?
No. Interpret it with the full clinical assessment, applicable entry criteria and current guidance.
References
- Khorana AA et al. Blood. 2008;111:4902-4907. — Primary or supporting reference for the implemented model.
Reviewed by: MedicalC Clinical Editorial Team
Last reviewed: July 2026
Clinical Disclaimer
MedicalC calculators and clinical tools are intended to support healthcare professionals. They do not replace clinical judgement, individual patient assessment, local guidance or specialist advice.
Results should always be interpreted in the context of the patient’s history, examination, investigations, current clinical condition and applicable professional guidance.
Related clinical knowledge
Explore referenced clinical guidance from the Medical & Dental Professional Development Alliance.
Venous thromboembolism in adults: diagnosis, anticoagulation and duration of treatment
An international guide to DVT and pulmonary embolism, integrating pre-test probability, D-dimer, imaging, anticoagulant selection, duration and recurrence risk.
Read on MDPDA ↗Acute coronary syndromes: early assessment, antithrombotic therapy and reperfusion
An international clinical guide to suspected STEMI, NSTEMI and unstable coronary syndromes, covering immediate assessment, ECG and troponin interpretation, antithrombotic treatment, invasive strategy and secondary prevention.
Read on MDPDA ↗HIV in adults: initial diagnosis, baseline assessment and antiretroviral therapy
An international professional guide to newly diagnosed HIV, covering confirmatory testing, baseline viral and immune assessment, rapid ART, resistance, co-infections and long-term prevention.
Read on MDPDA ↗